Clopidogrel is a commonly prescribed antiplatelet medication and prodrug used to prevent blood clots in patients with cardiovascular disease and stroke. Certain genetic variants reduce enzyme activity, leading to poor drug activation and an increased risk of treatment failure, while other variants enhance enzyme activity and may increase the risk of adverse side effects. Overall, the findings emphasize how integrating genetic information into clinical decision-making can support personalized medicine and help clinicians select safer and more effective treatments for individual patients.
